Sign In
CORT.US

Corcept Therapeutics (CORT) $14M Securities Settlement

N.D. California
Court
3:19-CV-01372
Case number
02 Aug 2017
Class period Start
31 Jan 2019
Class period End

Corcept Therapeutics (CORT) agreed to settle $14 million with investors to end a securities class action lawsuit over concealing that it improperly paid doctors to promote its drug Korlym and inflated its revenue and sales using illicit sales practices through a related party.


Investors who bought $CORT or call options to purchase common stock of Corcept between August 2, 2017, through January 31, 2019, inclusive, may be entitled to a payout.

Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.06
Filing date
14 March 2019
Lead Plaintiff Deadline
13 May 2019
Plaintiffs
Ferraro Family Foundation
Attorneys
Levi & Korsinsky, LLP (San Francisco, CA)
Defendants
Joseph K. Belanoff, Charles Robb, Sean Maduck
Judge
Hon. Lucy H. Koh
Administrator
A.B. Data Ltd
Settlement agreement date
2023-04-11
Trades matching type
FIFO
+$14,000,000
Total Settlement Amount
Created by Stan Vick, Scout

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offe...

    Ticker
    CORT.US
    ISIN
    US2183521028
    CIK
    1088856
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    149 Commonwealth Drive, Menlo Park, CA, United States, 94025